

DAFTAR PUSTAKA

1. Epilepsy Foundation of America. Definition of Epilepsy. [Online]. 2000 April [cited 2010];[3 screens]. Available from: [URL:http://www.bidneed.com/diagnostic_catagorics/article/epilepsydefenition.htm](http://www.bidneed.com/diagnostic_catagorics/article/epilepsydefenition.htm)
2. Engel J, Pedley TA. What is Epilepsy. In: Engel J. Jr, Pedley TA, Aicardi J, Dichter MA, Perucca E, Moshe SL, et al, editors. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1-3
3. Brodie MJ, Schachter S.C. Indispensable Guides to clinical Practice Epilepsy. 2nd. Oxford : Healt press; 2001.p.11-12
4. Dukan JS, Sander JW, Sisodiya SM, Walkers MC. Adult Epilesy. Lancet 2006 1;367:1087-100
5. Epilepsy Foundation of America. Epilepsy and Seizure Statistics. [Online]. 2008 [cited 2010 Nov 18];[2 screens]. Available from:[URL:http://www.epilepsfoundation.org/about/statistics.htm](http://www.epilepsfoundation.org/about/statistics.htm)
6. Wibowo S. Govir A. Obat Anti Epilepsi. Pustaka Cendekia Press. Yokyakarta; 2006 : 5-10
7. Pirmohamed M, Arroyo S, Idiosyncratic Adverse Reactions. In: Engel J. Jr, Pedley TA, Aicardi J, Dichter MA, Perucca E, Moshe SL, et al, editors. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1201-02
8. Saruwatari J, Ishitsu T, Nakagawa. Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals 2010;3:2709-732
9. Jackson J P. The Role of the nuclear receptoer CAR and PXR in the drug induced transcriptional regulation of the murine CYP2C subfamily of cytochromes P450 monooxygenases: access [dissertation]. Toxicology: Carolina State Univ.; 2006
10. Moreau A, Téruel C, Beylot M, Albalea V, Tamasi V, Umbdenstock T. et al. A Novel Pregnane X Receptor and S14-mediated lipogenic pathway in human

hepatocyte. Hepatology [serial online] 2009 [cited 2011 Apr 27]. Available from:URL:<http://www.montp.iserm.fr/u632/PDF/Moreau%20et%al.%20Hepatology%2009.pdf>

11. Anwar T.B. Dislipidemia sebagai faktor risiko penyakit jantung koroner. Universitas Sumatra Utara; 2004 : 2-3
12. Lee MH, Hong Il, Kim M, Lee BH, Kim JH, Kang KS, et al. Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicology and Applied Pharmacology 2007;220:45–59
13. Allan H, Ropper, Robert H, Brown, eds. Adam and Victor's. Principle of Neurology. 8th ed. New York: Mc Graw Hill Inc; 2005.p.294-5
14. Mintzer S, Mattson RT. Should enzyme-inducing antiepileptic drugs be considered first-line agents?. Epilepsia 2009;50(suppl.8):42-50
15. Mac T L, Tran D S, Quet F, Odermatt P, Preux P M, Tan C T. Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review. Lancet Neurol 2007;6:533-43
16. Mintzner S, Skidmore CT, Abidin CJ, Morales MC, Chervenova I, Capuzzi DM, et al. Effect of Antiepileptic On Lipids, Homocysteine, And Creactive Protein. Ann Neurol 2009;65:448-6
17. Trocho C, Gil JCE, Ribas V, Benitez S, Campos JMM, Rotllan N, et al, Phenytoin treatment reduces atherosclerosis in mice through mechanisms independent of plasma HDL-cholesterol concentration. Atherosclerosis 2004 Feb 25;174:275-85.
18. Kim J.Y, Lee H.W. Metabolic And Hormonal disturbances in Womans with epilepsy on Antiepileptic drugs monotherapy. Epilepsia 2007;48:1366-70
19. Janzky I, Hallqvist J, Tomson T, Ahlbom A, Mukamal KJ, Ahnve S. Increased risk and worse prognosis of myocardial infarction in patients with prior hospitalization for epilepsy—The Stockholm Heart Epidemiology Program. Oxf J Med. Brain. 2009;132(10):2798-804
20. Kumar P, Tyagi M, Tyagi YK, Kamar A, Kamar A, Rai YK. Effect Of Anticonvulsant Drugs On lipid profile in Epileptic Patients. The Internet Journal of Neurology [serial online] 2009 Sep 24 [cited 2010];3:[6 screens].

Available from: URL<http://www.spub.com/journal/the Internet journal of pharmacology volume/ 6 number /32/ article/ lipid lowering effect>.

21. Aynaci F.M.MD, Orhan F.MD, Oream A.MD, Yildirmis S.PhD, Gedik Y.MD. Effect Of Antiepileptic Drugs On Plasma Lipoprotein (A) and Other Lipid levels in childhood. J Child Neurol 2001;16:367-9
22. Gidal B.E. Assesing and preventing the metabolic side effects of antiepileptic drugs. Adv Study Nurs 2004;2(5):191-8
23. PedomanTata laksana Epilepsi. Kelompok studi epilepsi Perhimpunan Dokter Spesialis Saraf Indonesia. Jakarta: Badan Penerbit FK. UI; PERDOSSI 2003
24. Heinmann U, Mody I, Yaari Y. Control of Neuronal Excitability. In: Engel J. Jr, Pedley TA, Aicardi J, Dichter MA, Perucca E, Moshe SL, et al, eds. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 219-8
25. Noerjanto, D. Epidemiologi dan Diagnosis Epilepsi. dalam: Kustiowati E, Rahmawati D, Tugasworo D, editor. Peningkatan Kualitas Hidup Penyandang Epilepsi. Semarang: Badan Penerbit Universitas Diponegoro; 2001.p.3-11
26. Schmitz, B. Epilepsy. In: Ramachandran V.S, editors. The Human Brain. Humboldt University: Berlin; 2002. Vol 1. p. 202-4
27. Kustiowati E. Aspek Biomelekuler pada Epilepsi. Neurona Majalah Kedokteran Neuro-sains. Jakarta: PERDOSSI; 2003 ;21(1):4-6
28. Johannesen S I, Patsalos P N, Tomson T, Perucca E. Therapeutic Drug Monitoring. In: Engel J. Jr, Pedley TA, Aicardi J, Dichter MA, Perucca E, Moshe SL, et al, editors. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1179-81
29. Harsono. Epilepsi. 2nd ed. Gadjah Mada University press; 2007.p.7-13
30. Perucca E. General Principle of Medical Treatment. In: Shorvon S, Perucca E, Fish D, Dodson E, editors. The Treatment of Epilepsy. 2nd ed. Blackwell Science Ltd;2004.p.143-45
31. Karjalainen M. Inhibititon of CYP1A2 mediated drug metabolism in vitro and human: With special emphasis on refexocib and other NSAIDs: access and utilization [dissertation]. Helsinki: Medical Faculty of the univ.; 2008

32. Steven C, Schacter MD. Liver disease and drug metabolism [online] [2010?] [cited 2010 May 7];[1 screens]. Available from: URL:http://professional.epilepsy.com/page/gieffect_liverdis.html
33. Sepkuty JP, Kaplan PW. Hematologic disorders [online]. [2010?] [cited 2010 May 7];[1screens]. Available from: URL:http://professional.epilepsy.com/page/gieffect_hematologic.html
34. Garnett WR. Gastrointestinal disease and drug metabolisms epilepsy [Online] [2010?] [cited 2010 May 7];[1 screens]. Available from: URL:http://professionals.epilepsy.com/page/gieffect_giliver.html
35. Garnett WR. Carbamazepine: [online]. [2010?] [cited 2010 May 7];[1 screens]. Available from: URL:http://professionals.epilepsy.com/page/gieffect_carbmz.html
36. Garnett WR. Choosing and monitoring AEDs: [online]. [2010?] [cited 2010 May 7];[1 screens]. Available from: URL:http://professionals.epilepsy.com/page/gieffect_choose.html
37. Spina E, Perucca E, Levy R. Predictability of metabolic antiepileptic drug interactionsin. In: Majkowski J, Bourgeois B, Patsalos P, Mattson R, editor. Antiepileptic drugs combination therapy and interactions. Cambridge: University Press; 2005. p. 57-98
38. Mifsud J. The clinical relevance of pharmacokinetics and drug interactions with anti epileptic drugs. Journal of the Malta College of Pharmacy Practice 2009;(15):23-8
39. Pirmohamed M, Arroyo S, Idiosyncratic Adverse Reactions. In: Engel J. Jr, Pedley TA, Aicardi J, Dichter MA, Perucca E, Moshe SL, et al, editors. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1201-02
40. Pellock J M, Willmore L.J, Privitera M D. Rountin monitoring for safty and tolerability during chronic treatment with antiepileptic drugs. In: Engel J. Jr, Pedley TA, Aicardi J, Dichter MA, Perucca E, Moshe SL, et al, editors. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1311-13

41. Kowacs P.A, Junior E.B.S, Rocha S.F.B, Simao U, Meneses M.S. Severe Hypertriglyceridemia as a Carbamazepine-induced Paradoxical Effect. *J Epilepsy Clin Neurophysiol* 2005; 11(1):37-8
42. Bjorkhem I, Eggertsen G. Gene involved in initial steps of bile acid synthesis. *Curr Opin Lipidol* 2001;12:97-103
43. Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. *Archives of Biochemistry and Biophysics* 2004;1-7.
44. Sargowo D. Disfungsi endotel pada penyakit kardiovaskuler. Ed. Malang: Bayumedia Publishing; 2003.p.111-17
45. Verrotti A, Basciani F, Trotta D, Greco R, Morgese G, Ciarelli S. Effect of anticonvulsant drugs on interleukin-1,- 2, and -6 and monocyte chemoattractant protein-1: access [abstract]. *Clin exp Med* 2001;1:133-36
46. Wakkad A El, Hassan N El m, Sherif L, Shaheed A A El, Sibaii H, Zayat S. Hypercholesterolemia enhances the release of proinflammatory cytokines in obese Egyptian adolescents. *J Am Scie* 2010;6(8):428-35
47. Chabowski A, Zmijewska M, Gorski J, Bonen A, Kaminski K, Kozuch M, et al. IL-6 Deficiency increases fatty acid trasporters and intramuscular lipid content in but not white skeletal muscle. *J Physiol Pharm* 2008;59 Suppl 7:105-17
48. Hasahizume M, Yoshida H, Koike N, Suzuki M, Mihara M. Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. *Ann Rheum Dis* 2010;**69**:741-46
49. SAS Centres for Cardiovasculer Biomarkers Handbook [Online]. 2005 June [cited 2010 Des 14];[36 screens]. Available from: URL:<http://www.Sas-centre.Org/assays/cardiovasculer biomarkers/cardiovasculer.handbook.Pdf>
50. Lefton J.MS. RD. CNSD, Malon A. M. MS. RD. CNSD. Anthropometric Assessment, In: Charney P. RD, Malone A. M. MS. RD. CNSD. editors. Nutrition Assessment. 2nd ed. Chicago, Illinois: American Dietetic Association; 2009. p. 154-7
51. Saryono. Kumpulan instrumen penelitian kesehatan. Yogyakarta: Nuha Medika; 2010. p. 96-8

52. National Library of Medicine and National Institutes of Health. Cholesterol test. [Online]. 2010 June 6 [cited 2010 Des 15];[1 screens]. Available from: [URL:http://www.nlm.nih.gov/medlineplus/ency/article/003492.htm](http://www.nlm.nih.gov/medlineplus/ency/article/003492.htm)
53. National Library of Medicine and National Institutes of Health. LDL test. [Online]. 2010 May 23 [cited 2010 Des 15];[1 screens]. Available from: [URL:http://www.nlm.nih.gov/medlineplus/ency/article/003495.htm](http://www.nlm.nih.gov/medlineplus/ency/article/003495.htm)
54. National Library of Medicine and National Institutes of Health. HDL test. [Online]. 2010 May 23 [cited 2010 Des 15];[1 screens]. Available from: [URL:http://www.nlm.nih.gov/medlineplus/ency/article/003496.htm](http://www.nlm.nih.gov/medlineplus/ency/article/003496.htm)
55. National Library of Medicine and National Institutes of Health. Triglyceride Level. [Online]. 2010 May 23 [cited 2010 Des 15];[1 screens]. Available from: [URL:http://www.nlm.nih.gov/medlineplus/ency/article/003493.htm](http://www.nlm.nih.gov/medlineplus/ency/article/003493.htm)
56. Ghazali M.V, Sastromiharjo S, Soedjaerwo S.R, Soelaryo T, Pramulyo H.S. Studi *cross-sectional*, dalam: Sastroasmoro S, Ismael S, editor. Dasar-Dasar Metodologi Penelitian Klinis. 3rd ed. Jakarta: Sagung Seto; 2008. p. 114-25
57. Sastroasmoro S, Pemilihan subyek penelitian, dalam: Sastroasmoro S, Ismael S. eds. Dasar-Dasar Metodologi Penelitian Klinis. 3rd ed. Jakarta: Sagung Seto; 2008. p. 88
58. Roche Diagnostic (US). Cholesterol Gen.2. USA: Roche Group; 2003;2:EN
59. Roche Diagnostic (US). LDL-Cholesterol plus 2nd generation. USA: Roche Group; 2003;2:EN
60. Roche Diagnostic (US). HDL-Cholesterol plus 2nd generation. USA: Roche Group; 2003;2:EN
61. Roche Diagnostic (US). Triglycerides. USA: Roche Group; 2003;2:EN
62. Tumbelaka A.R, Riono P, Sastroasmoro S, Wirjdodiarjo M, Pujdiastuti P, Firman K. Pemilihan uji hipotesis, dalam: Sastroasmoro S, Ismael S. eds. Dasar-Dasar Metodologi Penelitian Klinis. 3rd ed. Jakarta: Sagung Seto; 2008. p. 279-99